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Abstract: Fluidity in cell fate or heterogeneity in cell identity is an interesting cell biological
phenomenon, which at the same time poses a significant obstacle for cancer therapy. The mammary
gland seems a relatively straightforward organ with stromal cells and basal- and luminal- epithelial
cell types. In reality, the epithelial cell fates are much more complex and heterogeneous, which is
the topic of this review. Part of the complexity comes from the dynamic nature of this organ: the
primitive epithelial tree undergoes extensively remodeling and expansion during puberty, pregnancy,
and lactation and, unlike most other organs, the bulk of mammary gland development occurs late,
during puberty. An active cell biological debate has focused on lineage commitment to basal- and
luminal- epithelial cell fates by epithelial progenitor and stem cells; processes that are also relevant to
cancer biology. In this review, we discuss the current understanding of heterogeneity in mammary
gland and recent insights obtained through lineage tracing, signaling assays, and organoid cultures.
Lastly, we relate these insights to cancer and ongoing efforts to resolve heterogeneity in breast cancer
with single-cell RNAseq approaches.
Keywords: mammary gland; breast cancer; cell fate; heterogeneity; 3D cultures; organoids; signaling;
single-cell RNAseq
1. Introduction into Mammary Gland Structure, Function and Early Development
The mammary gland is comprised of many different interacting cell types. Epithelial cells form a
primitive structure early during embryonic development, which later form the nipple and a ductal
network that expands into the fat pad. These epithelial ducts are surrounded by fat cells, and become
innervated with a variety of stromal cells including endothelial cells, immune cells, and fibroblasts [1].
Maturation of the gland is regulated at first by mesenchymal interactions, and later by hormone and
growth factor receptor signaling during puberty and pregnancy. Mammary epithelial cells assemble
into their normal morphology between E16-E18 (embryonic day), forming a bilayered duct with an
inner lumen [2]. Together, the mammary epithelial subtypes interact to carry out the organ’s functions.
After pregnancy, mature epithelial cells can later differentiate into alveolar cells and subsequently
produce milk proteins.
Mammary epithelial cells (MECs) typically form a bilayered epithelium and can be broadly
separated into two distinct compartments: an inner layer of luminal and outer layer of basal MECs.
However, additional heterogeneity exists within both luminal and basal MECs. Luminal populations
are often sub classified based on hormone and growth factor receptor status. The basal epithelium
contains a subset of so-called myoepithelial cells that lie along the outside of the ductal epithelial tree
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and assist in the motility of milk protein along the lumen. The MEC system also contains subsets of
basal and luminal stem and progenitor cells, which will be covered in greater detail later. For example,
within the luminal compartment a population of luminal progenitor cells can go on to form ductal
or alveolar cells. In addition, basal cells contain a subset of mammary stem cells (MaSCs) forming a
small, heterogeneous, and to date poorly defined population that drive development, repair and organ
reconstitution when transplanted into epithelium-cleared fat pads of recipient mice [3].
Puberty is the most dynamic and striking period during the development of the mammary
gland. The rudimentary duct undergoes significant expansion, resulting in the formation of bulbous
multilayered structures called terminal end buds (TEBs) [4] (Figure 1). TEBs are the proliferative
centers that drive elongation, bifurcation, and branching until the entirety of the mammary fat pad is
filled, thereby creating the mature epithelial tree [5]. The TEB contains cap cells, a rapidly growing and
dividing progenitor cell population that later goes on to form the tree’s outer myoepithelial layer [6].
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Transducer and Activator of Transcription 5A), a transcription factor activated by activated by ligands
including prolactin, growth hormone, and EGF (Epidermal Growth Factor) drives the expansion of
luminal progenitors and subsequent differentiation into alveolar cells [12].
Luminal progenitor populations can be distinguished using many of the above extracellular
markers. For example, ductal progenitors are CD61+, CD49b+, CD14+, and c-kit+ whereas their mature
counterparts are negative for the surface expression of these proteins [13–15]. Sca-1 (Spinocerebellar
ataxia type 1) expression can be used to separate ductal progenitors from alveolar progenitors since
alveolar progenitor cells lack membrane expression of the protein. It should be noted that expression
of these extracellular receptors is not ubiquitous between mouse model lines. Neither c-kit nor CD61
are expressed in mammary epithelial cells derived from C57BL/6 mice, while they are both found in
MECs from FVB/N mice [16]. The fate and biology of these luminal progenitor cell populations has
been further characterized by lineage tracing experiments, which we will discuss in Section 4.
3. Basal Cells and Progenitors
Unlike luminal cells, the factors that control and label different basal cell populations are
less clear. Both stem cells and bipotent progenitor cells have been identified within the broader
basal cell lineage. The use of extracellular markers to distinguish these discrete populations,
however, has not yet yielded clear profiles. Mature myoepithelial basal cells are typically
CD29hiCD49fhiCD24+EpCAMlo/med [7]. The undifferentiated population that is enriched for MaSCs is
believed to be CD49fhiCD29hiCD24hiEpCAMlo/medSca1−. Markers that are specific for a restricted basal
cell progenitor have not been identified and neither have specific markers for a restricted myoepithelial
cell progenitors. Luminal progenitors are thought to arise from an early basal cell population.
Several epithelial-mesenchymal transition (EMT) factors have been identified as molecular
regulators of the basal/MaSC population. The transcription factor Slug is a key for the basal/MaSC
lineage as it suppresses luminal cell fate. Slug-deficient mice have delayed ductal morphogenesis and
aberrantly express luminal signature genes in basal cell populations [17,18]. The transcription factor
Sox9 cooperates with Slug to suppress luminal fate and exogenous expression of these two factors
can convert differentiated luminal cells into MaSCs with long-term mammary gland-reconstituting
ability [18]. Tumor protein TP63 loss blocks the formation of the primitive epithelial duct [19]. Perhaps
one of the strongest drivers of basal cell identity, p63 overexpression in luminal cells leads to an identity
shift from luminal to a basal phenotype [20]. Notch1/3 signaling has been reported to down-regulate
TP63 expression as basal progenitors restrict to a luminal cell fate [21]. The transcription factor p53, on
the other hand, restricts basal/MaSC renewal and drives differentiation [22].
4. Lineage Tracing to Identify Restricted and Bipotent Progenitor Cells
Lineage tracing is a powerful tool to observe and track the function of adult-, stem- and
progenitor-cells during normal homeostasis, and various studies have utilized this approach to shed
light on the lineage hierarchies of the MECs. K8-creER targeted cells exclusively differentiate into
luminal cells when observed in vitro [23]. MECs marked with this label are maintained in small
numbers following several rounds of growth and differentiation. Elf5, a well-studied luminal progenitor
cell gene, was utilized in a separate study to trace this restricted progenitor population throughout
pubertal development [24]. Elf5-expressing cells exclusively produced mammary epithelial cells with
a luminal identity and were a major driver of branching morphogenesis [24]. In 2014, Rios et al.
confirmed that these Elf5-expressing cells were short-lived and restricted progenitors, as the positive
cells could not be detected in the mammary glands of lineage tracer mice after 20 weeks [24]. Combined,
these findings show that there may exist both short- and long-lived progenitor cells that exclusively
mature into luminal subtypes.
Lineage tracing studies were performed in order to hone-in on the exact nature of mammary
progenitor populations. In 2011, van Keymeulen et al. established that all mammary epithelial lineages
are derived from cytokeratin-14 (K14) expressing embryonic progenitors [23]. Following this population
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throughout puberty revealed that K14+ MaSCs promote basal expansion and maintenance. MaSCs
expressing K8 promoted luminal cell expansion and maintenance throughout puberty. When cultured
in vitro these restricted progenitors maintain their identity, while only basal cells display multipotency
in transplantation and reconstitution assays [23]. Rios et al. used lineage-tracing experiments to
identify a cytokeratin 5 (K5) expressing bipotent progenitor population [24]. K5-positive cells labeled
at the onset of puberty contributed to the formation of both mature luminal and myoepithelial cells.
5. Three-Dimensional Spheroid Cultures
In the late 1980s and early ′90s, three-dimensional (3D) cultures were instrumental in the discovery
of the cell biology of mammary gland development and breast cancer. We term these classical
three-dimensional spheroid cultures in our review, as these did not yet focus so much on the function
and preservation of stem cells through Wnt signaling. We will cover more on Wnt signals and organoids
later. For an excellent overview with historic perspectives on the development of these 3D culture
platforms we refer you to a review by Drs Simian and Bissell [25]. Essential for these revolutionary
in vitro approaches was the isolation of gel from the matrix of chondrosarcomas in 1977 by Orkin
and colleagues [26] that is now commonly known as Matrigel (Figure 2). For example, these classical
3D spheroid cultures revealed that a 3D basement membrane [27] impacts the response of a series
of human breast-tumor cell lines at different stages of progression, cultured within a physiological
context [28]. Importantly, the 3D aspect of these cultures revealed new discoveries, such as bidirectional
cross-modulation of integrin and EGFR (Epidermal Growth Factor Receptor) signaling, that were not
present in artificial 2D cultures [29].
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MaSC activity. Use of these platforms has allowed for new insights into the mechanisms by which
ductal morphogenesis is directed, particularly with regard to the role of different growth factor
receptors, which we discuss next.
6. EGFR Family and Ligands
The EGFR family consists of EGFR (ErbB1/Her1), ErbB2/Her2, ErbB3/Her3, and ErbB4/Her4. ErbB
receptors can both homo- and heterodimerize, with 10 possible combinations-six heterodimers and four
homodimers. There is a high level of homology between kinase domains of the four EGFRs (~60–80%)
with divergence occurring predominantly in the C terminus (shared identity is only ~10–25%). ErbB
proteins have tissue specific expression, though they are commonly expressed together. EGFRs are
found in several epithelial cell types such as the lung, intestine, and the breast. ErbB2 has no known
ligands (Table 1), but frequently dimerizes with the other three EGFR members because of its unique
and extended interaction loop [32]. ErbB3 is kinase dead, its cytoplasmic domain unable to initiate
phosphorylation cascades. ErbB3 is able to trans phosphorylate its own intracellular domain to assist
heterodimerization, as well as allosterically activate other EGFRs, however [33].
Table 1. The EGFR family members and their interacting ligands. Adapted from Hynes and Watson [34].
EGFR Family EGFR(ErbB1/Her1)
EGFR2
(ErbB2/Her2)
EGFR3
(ErbB3/Her3)
EGFR4
(ErbB4/Her4)
EGF X
TGF X
AREG X
EPG X
BTC X X
HB-EGF X X
EPR X X
NRG1 X X
NRG2 X X
NRG3 X
EGF: Epidermal Growth Factor; TGF: Transforming Growth Factor; AREG: Amphiregulin; EPG: Epigen; BTC:
Betacellulin; HB-EGF: Heparin-binding EGF-like growth factor; EPR: Epiregulin; NRG: Neuregulin; EGFR: Epidermal
Growth Factor Receptor; ErbB: Erythroblastic leukemia viral oncogene homolog; Her: Human epidermal growth
factor receptor.
Up to 13 different ligands have been found to bind EGFR family proteins: EGF, HB-EGF,
transforming growth factor (TGF), amphiregulin (AREG), epiregulin (EREG), epigen (EPG), betacellulin
(BTC), and neuregulins 1–6 (NRG) [34–36]. Ligand binding induces phosphorylation at tyrosine residues
on the cytoplasmic domain [37]. EGF and TGF are the key ligands for EGFR and ErbB3/B4 preferentially
bind neuregulins. The EGFR family members and their preferred ligands can be found in Table 1.
Evidence suggests that EGFR phosphorylation and the duration and amplitude of signaling events are
influenced by the binding of different ligands. This results in divergent cellular responses. For example,
AREG is more potent in stimulating ductal elongation compared to EGF [38]. These ligand-specific
nuances are important during development and cancer and we will cover some of the cancer-specific
nuances of EGFR signaling in Section 10.
7. EGFR during Mammary Gland Development
The vast majority of what is understood about the EGFR family’s role in mammary development
comes through the use of genetic mouse models. Egfr-deficient mice perish just after birth, which
complicated deciphering the exact nature of EGFR during mammary organogenesis [39,40]. Luetteke
et al. generated Waved-2 mice to circumvent this problem. The Waved-2 allele has a point mutation near
EGFR’s cytoplasmic kinase domain that reduces activity; it is hypomorphic [41]. Waved-2 mice have
defective mammary development with diminished branching and a reduction in ductal invasion [42,43].
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Use of a dominant negative EGFR protein using the mammary-specific MMTV promoter confirmed
its role during pubertal development. Mice with the dominant negative EGFR display reduced
proliferation and inhibited duct maturation [44]. Egfr’s importance in the stroma was confirmed via
the generation of mixed tissue recombinants from transplanting neonatal epithelial cells from wild
type or egfr-deficient mice [43,45,46].
Perturbations in other EGFR family genes also result in dramatic mammary developmental
phenotypes. Specifically, deficiency in the ErbB2–4 results in impaired ductal outgrowth during
puberty. Deletion of ErbB2 shunts ductal outgrowth [47,48]. ErbB2 also controls terminal end bud
(TEB) formation through its regulation of cellular compartmentalization. In summary, despite many
studies into the role of EGFR proteins in the mammary gland, the exact nature of each member has not
been fully elucidated. Stromal and epithelial expression of the EGFR family is critically important at
all stages of mammary development. A better understanding of EGFR and its downstream effectors is
needed to create a clearer picture of the signals and processes that regulate the complex process of
mammary organogenesis.
8. EGFR Signal Strength, Downstream Effector Kinases, Cell Fate
Mammary epithelial cells are organized into a developmental hierarchy based on extracellular
receptor and gene expression patterns. The exact nature of these populations, and the factors that
balance their proliferation with differentiation, are not well understood. Recent evidence has emerged,
however, that EGFR signaling in MECs may be a key player in better defining this hierarchy as depicted
in Figure 3.
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stimulation with the weak agonist AREG promoted luminal cell fate and a strong agonist (TGFα)
drove cells towards a basal cell identity. In contrast to the data presented in Pasic et al. [49], however,
Mukhopadhyay et al. found that EGF stimulation did not drive MaSCs down a specific lineage [50].
The addition of U0126, an inhibitor against the MEK-ERK pathway, significantly reduced differentiation
into CD49floEpCAMhi and EpCAMlo cells [50]. Taken together, it appears that the duration and
amplitude of EGFR signals affects MEC fate choices.
Since many of the signaling effectors triggered by the EGFR lay downstream of Ras, it is of interest
to consider the strength and duration of Ras activation as the cell fate determination factor. A historic
study reported that nuances in receptor-Ras signaling can affect cell fate in a PC-12 cell line system.
Stimulation of rat adrenal carcinoma cells (PC-12) with different EGFR ligands produced altered cell
fate. In the PC-12 system, EGF is a weaker agonist compared to the strong nerve growth factor (NGF).
EGF stimulation led to a short pulse of Ras-MEK-ERK activation and cell proliferation, while NGF
stimulation elicited prolonged Ras-MEK-ERK signals, exit from the cell cycle and differentiation [51].
Since that report in 1995, very little work has followed up on this, perhaps because it is challenging to
couple quantitative biochemical measurements to cell fate decisions, especially in in vivo studies.
9. EGFR and Other Receptor Tyrosine Kinases Signaling and Ductal Morphogenesis
Ductal morphogenesis is the process in which the mammary epithelium invades the fat pad
during puberty to form a fully branched ductal epithelial tree. It is known to occur in a somewhat
stochastic process, regulated by the combinatorial input of diverse signals. The stochastic aspect is
perhaps best exemplified by the fact that there are substantial differences between mammary glands of
mouse littermates. This has led the field to conclude that predetermined genetic control of pubertal
development is not a possibility, unlike in the development of other epithelial tissues [52]. Development
is dictated by mechanical factors and molecular signals from the surrounding stroma [53]. As a result,
maturation of the breast is context-dependent.
The pubertal developmental process is initiated in large part by the expression of ovarian
and pituitary hormones [54]. These signals cooperate to facilitate growth and communication
between epithelial and stromal cells. Genetic knockout of estrogen receptor alpha (ERα) leads to
incompletely developed mammary ductal trees, and exogenous administration of estrogen in mice
lacking ovaries rescues ductal morphogenesis [55,56]. Estrogen facilitates stromal cell expression of
hepatocyte growth factor (HGF) and epithelial expression of amphiregulin (AREG) [57,58]. AREG
can communicate with the epidermal growth factor receptor (EGFR), whose expression is essential on
mammary stromal cells [46]. Estrogen’s collective functions serve to regulate local cell growth during
pubertal development.
Estrogen is not the only steroid hormone important for pubertal mammary gland development,
however. In fact, estrogen alone is insufficient to restore ductal morphogenesis when other input (like
from the pituitary gland) is missing. Exogenous administration of growth hormone, normally produced
by the pituitary gland, can restore the impaired branching phenotype of pituitary gland-deficient
mice [59]. Growth hormone induces stromal insulin-like growth factor 1 (IGF1) expression, which
binds to IGFR on epithelial cells [60]. Together growth factor and IGF1 act as global regulators of
ductal morphogenesis.
Several growth factor receptors and receptor tyrosine kinases (RTKs) are involved in the integrated
signaling environment that directs mammary morphogenesis. Fibroblast growth factors (FGF) and their
receptors (FGFRs) are critically important for growth and branching. FGF2 and FGFR2 in particular
shape the profile of ductal outgrowth and MEC proliferation. Genetic deletion of fgfr2 disrupts
ectodermal and placode formation during embryonic mammary organogenesis [61]. Mammary
epithelial cells lacking fgfr2 have a proliferative disadvantage when compared to their wild-type and
fgfr2-heterozygous counterparts, and are depleted within TEBs [62]. Mice with inducible deletion of
fgfr2−/− reveal a similar phenotype; proliferation is significantly attenuated and TEBs are completely
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absent from the glands [63]. In summary, fgfr2 is a key regulator of luminal epithelial cells and it plays
a specific role in the TEBs of elongating ducts.
The EGFR family of signaling proteins plays a pivotal role in directing pubertal mammary gland
development in conjunction with FGF and FGF2. In brief, perturbations to each of the four EGFR
family members result in developmental defects. In ex vivo culture, FGF2 addition can rescue growth
and branching in EGFR-null 3D spheroids [45]. Mice with dominant negative EGFR display reduced
proliferation and inhibited duct maturation [44]. Deletion of ErbB2 shunts ductal outgrowth [47,48].
ErbB2 also controls TEB formation through its regulation of cellular compartmentalization. ErbB3
deficiency results in small TEBs and increased branch density with decreased TEB size as a result in
an increase in apoptosis, controlled via observed changes in the PI3K (Phosphoinositide 3-kinase)
signaling pathway. Anti-apoptotic transcription factor Bcl-2 is reduced in ErbB3−/− mice [64]. Mice
deficient for ErbB4 have defect occurring later in breast development, specifically during the formation
of milk-producing luminal cells [65].
10. ERFR in Breast Cancer and Oncogenic PI3K Signals That Switch Fate
Dr Schlessinger put forth an elegant and simple model for EGFR activation with EGF as an
external signal leading to the conversion of a monomeric receptor to a ligand-induced dimer [66],
which served as a framework for further studies. The EGFR dimer turned out to be an asymmetric
structure in which one EGFR kinase domain in a dimer acts as an allosteric activator for the other [67],
which subsequently paved the way to mechanistically understand how a catalytically inactive Her3
can facilitate the activation of other EGFRs, such as Her2 [68]. Her2 overexpression is frequently found
in breast cancer and typically associated with poor prognosis; a Her2/Her3 heterodimer operates as
an oncogenic unit that drives breast cancer proliferation [69], with the phosphorylated tyrosines in
the intracellular tail of the catalytically inactive Her3 functioning as adapter scaffolds for intracellular
kinases such as PI3K (Phosphoinositide 3-kinase) and PLC (Phospholipase C).
Whereas it is clear that the EGFR family plays a role in mammary gland development and
maturation as well as breast cancer, a lot less is known about the specific effector kinase pathways
that lie downstream of the receptor families such as the EGFR. Elegant imaging studies revealed
that levels of phosphorylated ERK kinases (a type of MAPK) are highest in MECs near the front of
elongating ducts whereas levels of phosphorylated Akt kinase were equal throughout and Huebner
et al. proposed a model of receptor-induced proliferation leading to highly motile cells with high
phospho-ERK [70]. Two thought-provoking studies relate cell fate choices to aberrant PI3K signals in
the context of breast cancer. Cell fate, heterogeneity, and cell lineage conversions are aspects that are
of great relevance to cancer as these impact the tumor type and also often responses to therapy [71].
PIK3CA (Phosphoinositide 3-kinase p110 alpha) with a histidine to arginine mutation at position 1047
(H1047R) is a frequent mutation occurring in human breast cancer and expression of PIK3CA(H1047R)
in lineage-committed basal Lgr5-positive and luminal keratin-8-positive cells led to dedifferentiation
into a multipotent stem-like state [72]. Furthermore, the tumor cell of origin influenced the frequency
of malignant breast tumors, linking (heterogeneous) cell fate to cancer aggressiveness [72]. Van
Keymeulen et al. reported similar results in their studies in the context of loss of the tumor suppressor
p53; expression of PIK3CA(H1047R) in basal cells (keratin K5-CreERT2 driver) gave rise to luminal-like
cells and expression in luminal cells (K8-CReERT2) resulted in basal-like cells before progressing into
invasive tumors [73]. Therefore, the rules that are thought to exist in normal unipotent progenitors
(see Figure 3) appear alter when cells express PIK3CA(H1047R), which brings up a bigger question.
What aberrant biochemical signals are capable to induce crossover of basal- and luminal-cell fates and
drive further increases in heterogeneity and fluidity between mammary epithelial cells?
11. The Mammary Stem Cell Conundrum: More Questions than Answers
While there is a general consensus about some of the factors that mark and or regulate the MaSC
population, the field has been left with more questions than answers when trying to specifically define
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MaSCs [74]. For example, the estimates for stem cell frequency, derived from calculating the number
of mammary repopulating units, varies dramatically. Estimates for MaSC frequency range from 1
in every 100 total cells to 1 in every 4900 [75–77]. Extracellular markers used to sort MaSCs have
proven insufficient to exclusively identify MaSC populations, but rather, only identify populations
within which MaSCs are enriched [78–80]. The embryonic stem cell marker Oct4 (Octamer-binding
transcription factor 4) has been found to label human mammary stem cells, but is insufficient to
specifically separate MaSCs from other progenitor cells [81,82].
Some progress has been made towards separating MaSCs from mature myoepithelial and basal
progenitors by using transgenic mouse models. MaSCs residing in the terminal end bud (TEB) cap
cells exclusively express the phosphatase s-Ship [83], but MaSCs during pubertal development are not
just found in cap cell populations. Lgr5, given its well-known role in intestinal epithelial populations,
became of interest as a potential marker of the MaSC population [84]. Again, the Lgr5 story is unclear
with opposing results of studies that use slightly different approaches. Whether Lgr5+ cells have
increased repopulating activity and whether they trend towards quiescence or self-renewal has not
been clearly delineated. The exact nature and potential of Lgr5+ and Lgr5-negative MaSC populations
is an ongoing field of research [85–87]. The Lgr5 question is emblematic of the larger picture that
MaSCs are a highly heterogeneous population. Isolating a basal population enriched for MaSCs from
fetal mice revealed a distinct stem cell identity. Fetal-derived MaSCs display augmented clonogenic
potency and repopulating efficiency when compared to their adult stem cell counterparts [88]. Further,
these fetal MaSCs expressed unique extracellular receptor pattern, one that has features of both basal
and luminal cells, which was also different from pubertal MaSCs [89]. The heterogeneity is further
compounded when looking at adult mammary glands. Adults MaSCs have been found to display
“lineage priming,” in which restricted differentiation programs exist within seemingly pluripotent and
self-renewal competent stem cells [90,91]. Recent RNAseq studies have begun to further subdivide the
MaSC pool. In 2017, Pal et al. found an early progenitor subset marked by CD55 that exists between
basal and luminal cells [92]. In sum, the spatial-, temporal-, and functional-heterogeneity of MaSCs
has made their study complicated and bolstered the importance of finding new regulatory factors.
In summary, in vitro and in vivo findings suggest that breast epithelial cells can be arranged into
a developmental hierarchy (Figure 3), but it should be explicitly stressed that this is just a model. In
this hierarchy, mature luminal and myoepithelial cells are maintained by lineage-restricted progenitors,
which is replenished by the MaSC population [93]. Bipotent progenitors exist within this hierarchy,
but the exact placement is unclear and has therefore been excluded. Extracellular ligand expression
and transcription factor regulation has served as the basis for the construction of this model. The
extraordinary complexity of the mammary stem cell population has complicated a clear understanding
of the drivers for epithelial cell fate decisions.
12. Organoids to Assess Stem- and Progenitor-Potential
Organoids are miniature, three-dimensional, in vitro tissue cultures that retain stem cell function,
and are generated from pieces of tissue (Figure 4). Organoids have been instrumental to study stem
cell biology of epithelial cell lineages [94,95]. They have gained traction as ideal platforms to screen
for biomarkers, obtain personalized predictive/prognostic information, and test novel therapeutic
strategies and rational drug design [96–98]. Organoids and classical mammosphere cultures are similar
in that both are in vitro 3D cultures of cells (Figures 2 and 4). However, organoids typically depend
more on the extracellular matrix and may display more self-organization and spatially restricted
lineage commitment [99].
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Furthermore, organoids can be cultured indefinitely and can be cryopreserved, whereas classical
mammosphere cultures generally survive for shorter time periods [100]. Indeed, several different
mammosphere cultures media cocktails have been applied in the past, but for many of these studies the
goal was not to sustain growth long term. For example, Mroue and Bissell used growth media containing
insulin transferrin selenium (ITS) and fetal bovine serum (FBS) for mammospheres generated from
mouse mammary glands, but cultures were not sustained for long periods of time in this study [101].
It should be noted that the use of FBS in organoid culture is challenging since the exact composition is
unknown and components can vary from batch-to-batch. Ewald et al., used growth media containing
ITS supplemented with FGF2 and cultures were grown and assessed for a couple of days [102].
A crucial part of successfully culturing organoids (Figure 4) is to preserve stem cell function
over long periods of time. The Wnt pathway has been shown to play an important role in stem
cell maintenance [103]. In the canonical Wnt pathway, Wnt proteins bind to Frizzled (FZD) and
LRP (lipoprotein receptor-related protein) receptors. Dickkopf (DKK) is a ligand that binds to
LRP6 with high affinity [104]. Wnt binding to FZD and LRP receptors results in increased levels
of β-catenin, which translocate into the nucleus to form a transcriptionally active complex with
Tcf factors (T cell factor) [105,106]. In the absence of Wnt signals, Tcf transcription factors bind to
Groucho repressors [107–109] and as such Tcf factors act as switches to turn on Wnt target genes [110].
Intriguingly, one of the β-catenin/Tcf target genes is the extracellular receptor Lgr5 [111]. R-spondins
are ligands for Lgr5 (Leucine-rich repeat-containing G-protein coupled receptor 5), and can associate
with the Frizzled/LRP Wnt receptor complex to enhance the Wnt signal [112]. Structure-based design
and subsequent production of surrogate Wnt ligands that are hybrid molecules combining the DKK
and Wnt ligands proved clever tools to sustain canonical Wnt signaling in combination with R-spondin
ligands and support efficient organoid growth [113].
In addition to surrogate Wnt and R-spondin ligands, EGF and Noggin are required to indefinitely
expand organoids [114]. Furthermore, additional components can be added to the organoid
medium to help maintain organoid cultures. These include fibroblast growth factor (FGF) 7, FGF10,
Activin like kinase inhibitor (A83-01), SB202190 (p38 mitogen-activated protein kinase inhibitor),
and nicotinamide [115]. Neuregulin 1 (Nrg1) is required for morphogenesis and differentiation
of the mammary gland [116]. Addition of Nrg1 to organoid culture medium resulted in higher
efficiency of mammary organoid generation [114]. Rho kinase inhibitor (Y-27632) was found to induce
indefinite proliferation in vitro in normal and tumor epithelial cells [117] and addition of Y-27632 to
organoid culture medium improved organoid culture conditions [114]. In Section 6 we discussed the
heterogeneity and complexity of the stem- and progenitor- cell population in the mammary gland with
Lgr5+ and Lgr5− cells and different characteristics in fetal-, puberty-, and adult-stages. We anticipate
that successful mammary gland organoids will require complex but clearly defined (growth) factor
medium and that systematic application of standard operating protocols (SOPs) will propel the field’s
efforts of organoid and cell heterogeneity forward.
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13. Reconstructing Mammary Epithelial Cell Types and States Using Single-Cell Genomics
Advances in next generation sequencing and microfluidic-based handling of cells and reagents
now enable us to explore cellular heterogeneity in an unbiased manner using various single-cell
genomics modalities to profile genomic features in individual cells [118]. The current scientific
knowledge about the MEC system is largely limited to data generated by bulk profiling methods, which
only provide averaged read-outs that generally mask cellular heterogeneity. This averaged approach is
particularly problematic when the biological effect of interest is limited to only a subpopulation of cells
such as stem/progenitor cells, which may comprise only minor subsets of the total number of cells in a
tissue. However, over the very recent years several studies emerged that utilized single-cell genomics
approaches for unbiased identification of the cell types and states within the MEC compartment.
Among the genomics modalities available to date, single-cell RNA sequencing (scRNAseq) is the
most advanced and most widely accessible to the research community, and has recently been applied
to both human and mouse mammary epithelial samples (Figure 5). A recent study using a combination
of microfluidic- and droplet-enabled single-cell transcriptomics pipelines revealed that the human
breast epithelium contains three very distinct types of cells that each contain additional distinct cell
states [119]. Based on these data, the human epithelium contains one basal and two luminal cell types,
namely a hormone-responsive and a secretory type of luminal cells. The secretory luminal cell type was
previously called luminal progenitors and generally expresses markers such as ELF5 (E74-like Facotr 5)
and KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, CD117). Within basal cells,
further distinctions can be made based on expression of myoepithelial markers (e.g., ACTA2, Actin
Alpha 2, Smooth Muscle). Pseudo temporal analysis of the differentiation trajectories in this dataset
defined a continuous lineage that seamlessly connected the basal and two luminal cell types, which is
in line with the concept that basal and luminal cell types are maintained by an integrated system of
stem and progenitor cells.
Cancers 2019, 11, x 11 of 19 
 
applied to both human and mouse mammary epithelial samples (Figure 5). A recent study using a 
combination of microfluidic- and droplet-enabled single-cell transcriptomics pipelines revealed that 
the human breast epithelium contains three very distinct types of cells that each contain additional 
distinct cell states [119]. Based on these data, the human epithelium contains one basal and two 
luminal cell types, namely a hormone-responsive and a secretory type of luminal cells. The secretory 
luminal cell type was previously called luminal progenitors and generally expresses markers such as 
ELF5 (E74-like Facotr 5) and KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, 
CD117). Within basal cells, further distinctions can be made based on expression of myoepithelial 
markers (e.g., ACTA2, Actin Alpha 2, Smooth Muscle). Pseudo temporal analysis of the 
differentiation trajectories in this dataset defined a continuous lineage that seamlessly connected the 
basal and two luminal cell types, which is in line with the concept that basal and luminal cell types 
are maintained by an integrated system of stem and progenitor cells. 
 
Figure 5. Pipeline of scRNAseq to resolve cellular heterogeneity with novel sequencing techniques. 
Processing mammary gland tissue of breast cancers into single-cell droplets coupled to single-cell 
RNA sequencing (scRNAseq) and data analysis (e.g., tSNE plots) allows for high resolution 
investigation of different cell types on the basis of individual cell transcriptome. 
The mouse mammary epithelium at post-pubertal stage generally revealed a comparable cell 
type and state composition with some differences in terms of marker genes expressed in each cell 
type. Pal et al. [92] used scRNAseq of isolated mouse MECs to define three main cell types, namely 
basal (marked by Krt14, Keratin 14), secretory luminal or also called luminal progenitors (L-sec; 
marked by Elf5) and mature, hormone-responsive luminal cells (L-HR; marked by Prlr, Prolactin 
receptor). In addition to the main cell types, intermediate states were identified marked by expression 
of both luminal and basal genes, which could be indicative of transitional cell states between luminal 
and basal cells and thus support the notion of one continuous lineage trajectory that maintains all 
MEC cell types. Another similar study focused on the differentiation dynamics of the mouse 
mammary epithelium during various developmental stages of adult virgin, pregnant, lactating and 
involuting mammary gland using scRNAseq, which defined the lineage hierarchies as a 
differentiation continuum rather that discrete differentiation stages [120]. The most elusive cell type 
remains the MaSC, which so far did not emerge as a distinct cluster in either human or mouse single-
cell transcriptomics analyses, although a subset of basal cells in both human and mouse cells 
expresses the putative MaSC markers PROCR (Protein Coding, CD201) or LGR5 [119,120]. It remains 
to be determined whether more sophisticated analysis tools such as single-cell potency analysis [121], 
or higher sequencing depth per cell and larger cell numbers are required to unambiguously define 
the MaSC as a distinct cell type (Figure 5). Recent years have also seen the emergence of studies that 
applied scRNAseq to unravel complexity of breast cancer [122,123], including the immune 
environment of breast tumors [124,125], and response to Herceptin therapy that targets EGFR2 (Her2) 
[126]. More is certainly to come as scRNAseq and its analysis becomes more mainstream and 
affordable. 
In addition to gene expression programs, the epigenetic makeup of the cell is a critical 
determinant of cellular identity that is not detectable in scRNAseq data. Recent technological 
advances now allow for profiling chromatin accessibility using the Assay for Transposase-Accessible 
Chromatin using sequencing (ATACseq) to reconstruct cis/trans regulatory elements associated with 
cellular identity [127]. Further adaptation of this pipeline enabled single-cell-level ATACseq to profile 
cellular heterogeneity on an epigenetic level both using massively parallel [128] and combinatorial 
Figure 5. Pipeline of scRNAseq to resolve cellular heterogeneity with novel sequencing techniques.
Processing mammary gland tissue of breast cancers into single-cell droplets coupled to single-cell RNA
sequencing (scRNAseq) and data analysis (e.g., tSNE plots) allows for high resolution investigation of
different cell types on the basis of individual cell transcriptome.
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subset of basal cells in both human and mouse cells expresses the putative MaSC markers PROCR
(Protein Coding, CD201) or LGR5 [119,120]. It remains to be determined whether more sophisticated
analysis tools such as single-cell potency analysis [121], or higher sequencing depth per cell and
larger cell numbers are required to unambiguously define the MaSC as a distinct cell type (Figure 5).
Recent years have also seen the emergence of studies that applied scRNAseq to unravel complexity of
breast cancer [122,123], including the immune environment of breast tumors [124,125], and response
to Herceptin therapy that targets EGFR2 (Her2) [126]. More is certainly to come as scRNAseq and its
analysis becomes more mainstream and affordable.
In addition to gene expression programs, the epigenetic makeup of the cell is a critical determinant
of cellular identity that is not detectable in scRNAseq data. Recent technological advances now
allow for profiling chromatin accessibility using the Assay for Transposase-Accessible Chromatin
using sequencing (ATACseq) to reconstruct cis/trans regulatory elements associated with cellular
identity [127]. Further adaptation of this pipeline enabled single-cell-level ATACseq to profile cellular
heterogeneity on an epigenetic level both using massively parallel [128] and combinatorial indexing
methods [129]. This approach has recently been applied to elucidate transcriptional regulators of the
fetal mammary gland developmental lineages showing that fetal MaSCs can be separated into basal-like
and luminal-like lineages, suggesting an early lineage segregation prior to birth [130]. Another study
utilized a combination of single-cell ATAC and RNA sequencing isolated mammary epithelial cells
to reveal the spectrum of heterogeneity within the MEC system in the adult stage [131] Interestingly,
a distinct luminal progenitor cell state within the secretory luminal cell type emerged in chromatin
accessibility analysis that was clustering separately in transcriptomics data. By integrating single-cell
transcriptomics and chromatin accessibility landscapes, this work further identified novel cis- and
trans-regulatory elements that are differentially activated in the epithelial cell types and the newly
defined progenitor cell state. Taken together, these single-cell genomics studies provide invaluable
resources that may serve as reference atlases to map out how the system goes awry during diseases
such as cancer in unprecedented resolution.
14. Conclusions
In summary, cartoons such as the one depicted in Figure 3 in our review give the impression of
simple and clean cell lineage choices with well-defined trajectories of cell development in unipotent
manners. In reality the mammary gland, and therefore breast cancer, is much more complex and
cellular heterogeneity is obvious. The pair of studies using expression of oncogenic PIK3CA(H1047R)
in different mammary epithelium cell subsets give particularly striking examples of crossover between
basal- and luminal- cell fates and the possibility of dedifferentiation into a multipotent stem-like
state [71,72]. It is not difficult to imagine how such fluidity in cell identity may greatly impact how
breast cancer patients respond to specific types of therapy in the clinic. Fortunately, technology is
constantly evolving. For example, studies that assess the potential of cell populations with organoids
coupled to characterization of the transcriptional landscape at the single-cell level are starting to emerge
(Figure 6). Intelligent combination of organoids, mouse models, scRNAseq, ATACseq, lineage tracing,
CyTOF (mass cytometry by time-of-flight), and other novel technology platforms will be required to
comprehensively understand cell heterogeneity in the mammary gland and breast cancer.
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